The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase (ph) I safety data.
Kathleen Neville
No relevant relationships to disclose
Lia Gore
No relevant relationships to disclose
Christine Mauz-Körholz
No relevant relationships to disclose
Angelo Rosolen
No relevant relationships to disclose
Judith Landman-Parker
No relevant relationships to disclose
Jose Sanchez de Toledo
No relevant relationships to disclose
Auke Beishuizen
No relevant relationships to disclose
Anna Rachel Keating Franklin
Research Funding - Millennium
Adedigbo Fasanmade
Employment or Leadership Position - Millennium
Jingyuan Wang
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Dirk Huebner
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Franco Locatelli
No relevant relationships to disclose